相关实验视频
Updated: May 11, 2026

05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 10, 2014
抗逆转录病毒治疗失败后的双或单个蛋白酶抑制剂疗法:随机试验
Scott M Hammer1, Florin Vaida, Kara K Bennett
1Division of Infectious Diseases, Department of Medicien, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA. smh48@columbia.edu
JAMA
|July 4, 2002
概括
将第二个蛋白酶抑制剂 (PI) 添加到4种药物治疗方案中,改善了治疗失败的HIV患者的病毒载荷抑制. 有利的结局与双PI使用,没有先前的非核酸逆转录酶抑制剂 (NNRTI) 暴露以及药物过敏性有关.
科学领域:
- 病毒学和免疫学 病毒学和免疫学
- 抗逆转录病毒疗法研究研究
- 临床试验在传染病中的临床试验
背景情况:
- 在含有蛋白酶抑制剂 (PI) 治疗方案的患者中,管理抗逆转录病毒治疗失败会带来重大治疗挑战.
- 优化人类免疫缺陷病毒 (HIV) 感染的治疗策略需要仔细考虑药物组合和患者病史.
研究的目的:
- 为了评估将第二个PI纳入4种药物治疗方案中的抗病毒疗效,用于经历病毒学失败的患者.
- 为了确定是否添加第二个PI增强了艾滋病毒感染者的病毒载荷抑制,先前PI暴露.
主要方法:
- 一个多中心,随机,双盲,安慰剂对照试验,涉及481名艾滋病毒感染者,病毒载量>1000副本/毫升.
- 参与者被分配给接受4种药物治疗方案,包括阿姆普雷纳维尔,阿巴卡维尔,埃法维伦兹和阿德福维尔迪皮沃克西尔,再加上第二种PI (萨基纳维尔,印尼纳维尔或内尔菲纳维尔) 或安慰剂.
- 主要终点是24周病毒载量<200副本/毫升;次要终点包括病毒载量变化,CD4计数,不良事件和药物敏感性.
主要成果:
- 总体而言,31%的患者在24周后的病毒载量低于200副本/毫升.
- 双PI手臂的病毒抑制率 (35%) 与安慰剂手臂 (23%;P=.002) 相比显著更高.
- 之前使用过非核酸逆转录酶抑制剂 (NNRTI) 的患者比使用过非核酸逆转录酶抑制剂 (NNRTI) 的患者 (16%) 有更好的病毒抑制 (43%). 基线对efavirenz的过敏性也与有利的结果相关.
结论:
- 包含4或5种新药的疗法,包括第二种PI,在31%的经验丰富的抗逆转录病毒药物患者中实现了病毒载荷抑制.
- 与成功的病毒载荷抑制相关的关键因素包括使用两种PI,缺乏先前的NRTI暴露,以及对efavirenz的基线过敏度.
相关概念视频
Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

